InfuSystem Reports Third Quarter 2024 Financial Results

Rhea-AI Summary

InfuSystem Holdings reported strong Q3 2024 financial results with record net revenues of $35.3 million, up 11% year-over-year. Net income increased 162% to $1.8 million ($0.08 per diluted share). Patient Services revenue grew 8% to $20.8 million, while Device Solutions revenue rose 15% to $14.5 million. The company's gross margin improved to 53.9%, up 5.0%. Adjusted EBITDA reached $7.9 million, increasing 27% with margin expansion to 22.3%. Operating cash flow surged 91% to $12.5 million. The company entered new strategic partnerships with Smith+Nephew for wound therapy and became exclusive distributor of Chemo Mouthpiece® through SI Healthcare Technologies joint venture.

Positive

• Record quarterly revenue of $35.3 million, up 11% YoY
• Net income surge of 162% to $1.8 million
• Gross margin improvement of 5.0% to 53.9%
• Operating cash flow increased 91% to $12.5 million
• Adjusted EBITDA grew 27% to $7.9 million with margin expansion to 22.3%

Negative

• G&A expenses increased 16.8% to $12.8 million
• G&A expenses as percentage of revenue increased to 36.2% from 34.3%

Insights

Financial Analyst

InfuSystem delivered strong Q3 2024 results with several notable achievements. Net revenues reached a record $35.3 million, showing 11% growth, while net income surged 162% to $1.8 million. The company demonstrated robust operational efficiency with Adjusted EBITDA margin expanding to 22.3%.

Key performance indicators show healthy business fundamentals:

• Patient Services revenue grew 8% with improved margins
• Device Solutions revenue increased 15%
• Operating cash flow jumped 91% to $12.5 million
• Available liquidity of $46.9 million provides strong financial flexibility

The company's strategic partnerships with Smith+Nephew and SI Healthcare Technologies position it well for future growth. The debt-to-EBITDA ratio of 1.15x indicates a healthy balance sheet, supporting continued expansion and operational investments.

Medical Equipment Analyst

InfuSystem's performance in medical equipment services shows strategic diversification and market penetration. The 89.5% increase in medical equipment sales and 16% growth in rental revenue demonstrate strong demand for their services. The expansion into negative pressure wound therapy through the Smith+Nephew partnership and the exclusive distribution rights for Chemo Mouthpiece® significantly broaden their market reach.

The improved gross margins in both Patient Services (66%) and Device Solutions (36.7%) segments indicate effective cost management and pricing strategy. The company's focus on high-margin rental business and strategic equipment deployment shows sophisticated market positioning in the medical device services sector.

Record Net Revenues of $35.3 million Representing 11% Growth from the Prior Year

Net income of $1.8 million, an increase of 162%

Adjusted EBITDA (non-GAAP) margin expanded by 2.8% to 22%

Reaffirms Full-Year 2024 Guidance

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)-- InfuSystem Holdings, Inc. (NYSE American:INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the third quarter ended September 30, 2024.

2024 Third Quarter Overview:

• Net revenues totaled $35.3 million, an increase of 11% vs. prior year.
  • Patient Services net revenue was $20.8 million, an increase of 8% vs. prior year.
  • Device Solutions net revenue was $14.5 million, an increase of 15% vs. prior year.
• Gross profit was $19.0 million, an increase of 22% vs. prior year.
• Gross margin was 53.9%, an increase of 5.0% vs. prior year.
  • Patient Services gross margin was 66.0%, an increase of 4.6% vs. prior year.
  • Device Solutions gross margin was 36.7%, an increase of 6.7% vs. prior year.
• Net income increased 162.3% to $1.8 million, or $0.08 per diluted share vs. prior year net income of $0.7 million, or $0.03 per diluted share.
• Adjusted earnings before interest, income taxes, depreciation, and amortization (“Adjusted EBITDA”) (non-GAAP) was $7.9 million, an increase of 27% vs. prior year.
• Adjusted EBITDA (non-GAAP) margin increased 2.8% to 22.3% vs. 19.5% prior year.
• Net operating cash flow was up 91% to $12.5 million, as of September 30, 2024.
• Company liquidity totaled $46.9 million, as of September 30, 2024.

Management Discussion

Richard DiIorio, Chief Executive Officer of InfuSystem, said, “Our third quarter financial results reflect the forecasted acceleration in our business in the second half of the year. We saw significant growth in both our top- and bottom-line results, accompanied by strong cash flow. The record revenue of $35.3 million which represents organic growth of 11% was driven by strong growth in our oncology and rental businesses, and ramping revenue in wound care third-party payer revenues. Our cash flow from operations in the quarter was very strong coming in at $9.8 million and was used to pay down debt and repurchase stock as part of our repurchase program.”

“During the quarter, we entered into two new strategic partnerships. In August, we issued a press release announcing the new distribution agreement with Smith+Nephew for negative pressure wound therapy. In September, we announced that SI Healthcare Technologies, our joint venture with Sanara MedTech, became the exclusive distributor of the Chemo Mouthpiece®, an oral cryotherapy device with FDA 510(k) clearance, that will be marketed to approximately 3,000 cancer centers in the United States. Each of these opportunities will help drive growth going into 2025.”

“Our core businesses, oncology and equipment rentals and sales, continue to grow and deliver strong operating returns as we pursue and ramp our major strategic initiatives in wound care and biomedical services. Our momentum is strong and we are excited about the future of InfuSystem. I am immensely proud of our team, as these results are a testament to their dedication, execution, and unwavering commitment to our patients and the inherent strength of our business,” concluded Mr. DiIorio.

2024 Third Quarter Financial Review

Net revenues for the quarter ended September 30, 2024 were $35.3 million, an increase of $3.4 million, or 10.7%, compared to $31.9 million for the quarter ended September 30, 2023. The increase included higher net revenues for both the Patient Services and Device Solutions segments.

Patient Services net revenue of $20.8 million increased $1.5 million, or 7.7%, during the third quarter of 2024 compared to the prior year period. This increase was primarily attributable to additional treatment volume and increased third-party payer collections totaling $2.4 million, offset partially by $1.0 million lower revenue from sales-type leases of NPWT pumps. The improved volume and collections benefited Oncology revenue by $1.8 million or 10.7%, Pain Management revenue by $0.2 million, or 14.3%, and Wound Care treatment revenue by $0.5 million, or 219%. Sales-Type Lease revenue of NPWT pumps, which had a tough comparison to an unusually strong prior year amount, decreased by $1.0 million.

Device Solutions net revenue of $14.5 million increased $1.9 million, or 15.2%, during the third quarter of 2024 compared to the prior year period. This increase included increased medical equipment sales of $1.1 million, or 89.5%, and higher rental revenue totaling $0.7 million, or 16.0%. Higher medical equipment sales were due to a large sale to an existing rental customer and reflects how timing for large contracts can vary from quarter-to-quarter. The increases in rental revenue was mainly attributable to a new customer added during the 2024 second quarter.

Gross profit for the third quarter of 2024 of $19.0 million increased by $3.4 million, or 22.0%, compared to the third quarter of 2023. This increase was due to the increase in net revenues and by a higher gross profit percentage of net revenue ("gross margin"). Gross margin was 53.9% during the third quarter of 2024 compared to 48.9% during the prior year period, an increase of 5.0%. Gross profit and gross margin were each higher in both the Patient Services and Devices Solutions segments.

Patient Services gross profit was $13.7 million during the third quarter of 2024, representing an increase of $1.9 million, or 15.8%, compared to the prior year period. The increase reflected the higher net revenue and higher gross margin, which increased from the prior year by 4.6% to 66.0%. The increase in gross margin reflected increased third-party payer collections, favorable gross margin mix and improved coverage of fixed costs from higher net revenue. The favorable gross margin mix was mainly related to the decrease in revenue related to NPWT equipment leases which had lower average gross margin than other Patient Services revenue categories.

Device Solutions gross profit during the third quarter of 2024 was $5.3 million, representing an increase of $1.6 million, or 41.2%, compared to the prior year. This increase was due to the increase in net revenue and an increased gross margin. The Device Solutions gross margin was 36.7% during the current quarter, which was 6.7% higher than the prior year period. The increase was due to favorable sales mix involving higher margin products including rental revenue and sales of used medical equipment.

Selling and marketing expenses were $2.8 million for the third quarter of 2024, representing an increase of 1.0%, compared to the prior year. Selling and marketing expenses as a percentage of net revenues decreased to 7.8% compared to 8.5% in the prior year period. This decrease reflected a reduction in sales team members and improved coverage of fixed costs from higher net revenues.

General and administrative ("G&A") expenses for the third quarter of 2024 were $12.8 million, an increase of $1.8 million, or 16.8%, from the third quarter of 2023. This increase included increased stock-based compensation expenses of $0.2 million, increased accrued incentive compensation totaling $0.3 million, an increase in accrued bad debt expense of $0.2 million and $0.3 million of expenses not incurred in 2023 related to a project to upgrade the Company's information technology and business applications. Other increased expenses totaling $0.8 million were associated with revenue volume growth including the cost of additional personnel, information technology and general business expenses and included inflationary increases. G&A expenses as a percentage of net revenues for the third quarter of 2024 increased to 36.2% from 34.3% for the prior year period.

Net income for the third quarter of 2024 was $1.8 million, or $0.08 per diluted share, compared to net income of $0.7 million, or $0.03 per diluted share, for the third quarter of 2023.

Adjusted EBITDA, a non-GAAP measure, for the third quarter of 2024 was $7.9 million, or 22.3% of net revenue, and increased by $1.7 million, or 26.6%, compared to Adjusted EBITDA for the same prior year quarter of $6.2 million, or 19.5% of prior period net revenue.

Balance sheet, cash flows and liquidity

During the nine-month period ended September 30, 2024, operating cash flow increased to $12.5 million, a $6.0 million, or 91%, increase over operating cash flow during the same prior year nine-month period. The increase reflected higher operating income and lower working capital growth during 2024 as compared to 2023. Capital expenditures during the nine-month period of 2024 included purchases of medical devices totaling $12.2 million, which was $3.7 million, or 43%, higher than the amount purchased during the same prior year period. Purchases of medical equipment were higher during 2024 compared to 2023 because a higher portion of the revenue growth in 2024 came from rental revenues that require capital equipment purchases.

As of September 30, 2024, available liquidity for the Company totaled $46.9 million and consisted of $46.5 million in available borrowing capacity under its revolving line of credit plus cash and cash equivalents of $0.4 million. Net debt, a non-GAAP measure (calculated as total debt of $28.0 million less cash and cash equivalents of $0.4 million) as of September 30, 2024 was $27.6 million representing a decrease of $1.3 million compared to net debt of $28.9 million as of December 31, 2023 (calculated as total debt of $29.1 million less cash and cash equivalents of $0.2 million). Our ratio of Adjusted EBITDA to net debt (non-GAAP) for the last four quarters was 1.15 to 1.00 (calculated as net debt of $27.6 million divided by Adjusted EBITDA of $24.0 million).

Full Year 2024 Guidance

InfuSystem is reaffirming its annual guidance for the full year 2024 with net revenue growth estimated to be in the high-single-digit range and forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 17.8% in 2023.

The full year 2024 guidance reflects management’s current expectation for operational performance, given the current market conditions. This includes our best estimate of revenue and Adjusted EBITDA. These estimates include expected expenses related to planned upgrades of the Company's information technology and business applications. The Company and its businesses are subject to certain risks, including those risk factors discussed in our most recent annual report on Form 10-K for the year ended December 31, 2023, filed on April 10, 2024.

Conference Call

The Company will conduct a conference call for all interested investors on Thursday, November 7, 2024, at 9:00 a.m. Eastern Time to discuss its third quarter 2024 financial results. The call will include discussion of Company developments, forward-looking statements and other material information about business and financial matters.

To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company’s website at https://ir.infusystem.com/. A replay of the call will be available by visiting https://ir.infusystem.com/ for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, replay access code 7261158, through November 14, 2024.

Non-GAAP Measures

This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. Non-GAAP financial measures presented in this press release include EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, net debt and Adjusted EBITDA to net debt ratio. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company’s management, investors and other interested parties about the Company’s operating performance because they allow them to understand and compare the Company’s operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for non-recurring or non-core items that are not part of the normal course of business. A reconciliation of those measures to the most directly comparable GAAP measures is provided in the accompanying schedule, titled "GAAP to Non-GAAP Reconciliation" below. Future period non-GAAP guidance includes adjustments for items not indicative of our core operations, which may include, without limitation, items included in the accompanying schedule below. Such adjustments may be affected by changes in ongoing assumptions and judgments, as well as non-core, nonrecurring, unusual or unanticipated changes, expenses or gains or other items that may not directly correlate to the underlying performance of our business operations. The exact amounts of these adjustments are not currently determinable but may be significant. It is therefore not practicable to provide the comparable GAAP measures or reconcile this non-GAAP guidance to the most comparable GAAP measures and, therefore, such comparable GAAP measures and reconciliations are excluded from this release in reliance upon applicable SEC staff guidance.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. (NYSE American:INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

Forward-Looking Statements

The financial results in this press release reflect preliminary results, which are not final until the Company’s quarterly report on Form 10-Q for the quarter year ended September 30, 2024 is filed. In addition, certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, strategic partnerships, growth initiatives, objectives and prospects, future operating or financial performance, guidance and expected new business relationships and the terms thereof (including estimated potential revenue under new or existing contracts). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “goal,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our ability to successfully execute on our growth initiatives and strategic partnerships, our ability to enter into definitive agreements for the new business relationships on expected terms or at all, our ability to generate estimated potential revenue amounts under new or existing contracts, the uncertain impact of disruptions caused by public health emergencies or extreme weather or other climate change-related events, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, systemic pressures in the banking sector, including disruptions to credit markets, the Company's ability to remediate its previously disclosed material weaknesses in internal control over financial reporting, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Company’s most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. Our strategic partnerships are subject to similar factors, risks and uncertainties. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.

Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

FINANCIAL TABLES FOLLOW

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
	Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands, except share and per share data)		2024				2023				2024				2023
Net revenues	$	35,320			$	31,909			$	101,013			$	94,014
Cost of revenues		16,275				16,293				48,826				47,616
Gross profit		19,045				15,616				52,187				46,398
Selling, general and administrative expenses:
Amortization of intangibles		248				248				743				743
Selling and marketing		2,755				2,728				9,173				8,937
General and administrative		12,777				10,943				37,996				33,880
Total selling, general and administrative		15,780				13,919				47,912				43,560
Operating income		3,265				1,697				4,275				2,838
Other expense:
Interest expense		(476	)			(563	)			(1,416	)			(1,667	)
Other expense		(4	)			(14	)			(64	)			(47	)
Income before income taxes		2,785				1,120				2,795				1,124
Provision for income taxes		(978	)			(431	)			(1,383	)			(324	)
Net income	$	1,807			$	689			$	1,412			$	800
Net income per share:
Basic	$	0.08			$	0.03			$	0.07			$	0.04
Diluted	$	0.08			$	0.03			$	0.07			$	0.04
Weighted average shares outstanding:
Basic		21,290,512				21,095,404				21,271,858				20,968,711
Diluted		21,652,457				21,719,404				21,707,835				21,615,706

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS SEGMENT REPORTING (UNAUDITED)
		Three Months Ended September 30,								Better/ (Worse)
(in thousands)			2024				2023
Net revenues:
Patient Services		$	20,780			$	19,289			$	1,491
Device Solutions			16,532				14,218				2,314
Less: elimination of inter-segment revenues (a)			(1,992	)			(1,598	)			(394	)
Total Device Solutions			14,540				12,620				1,920
Total			35,320				31,909				3,411
Gross profit:
Patient Services			13,710				11,837				1,873
Device Solutions			5,335				3,779				1,556
Total		$	19,045			$	15,616			$	3,429

(a)	Inter-segment allocations are for cleaning and repair services performed on medical equipment.

		Nine Months Ended September 30,								Better/ (Worse)
(in thousands)			2024				2023
Net revenues:
Patient Services		$	59,617			$	57,382			$	2,235
Device Solutions			46,843				41,541				5,302
Less: elimination of inter-segment revenues (a)			(5,447	)			(4,909	)			(538	)
Total Device Solutions			41,396				36,632				4,764
Total			101,013				94,014				6,999
Gross profit:
Patient Services			39,428				35,223				4,205
Device Solutions			12,759				11,175				1,584
Total		$	52,187			$	46,398			$	5,789

(a)	Inter-segment allocations are for cleaning and repair services performed on medical equipment.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES GAAP TO NON-GAAP RECONCILIATION (UNAUDITED)
NET INCOME TO EBITDA, ADJUSTED EBITDA, NET INCOME MARGIN AND ADJUSTED EBITDA MARGIN:
		Three Months Ended September 30,								Nine Months Ended September 30,
(in thousands)			2024				2023				2024				2023
GAAP net income		$	1,807			$	689			$	1,412			$	800
Adjustments:
Interest expense			476				563				1,416				1,667
Income tax provision			978				431				1,383				324
Depreciation			2,897				2,820				8,335				8,621
Amortization			248				248				743				743
Non-GAAP EBITDA		$	6,406			$	4,751			$	13,289			$	12,155
Stock compensation costs			1,221				1,063				3,276				2,799
Medical equipment reserve and disposals (1)			241				307				368				1,073
Management reorganization/transition costs			—				—				108				72
Cooperation Agreement payment and associated legal expenses			—				—				649				—
Certain other non-recurring costs			—				96				109				114
Non-GAAP Adjusted EBITDA		$	7,868			$	6,217			$	17,799			$	16,213
GAAP Net Revenues		$	35,320			$	31,909			$	101,013			$	94,014
Net Income Margin (2)			5.1	%			2.2	%			1.4	%			0.9	%
Non-GAAP Adjusted EBITDA Margin (3)			22.3	%			19.5	%			17.6	%			17.2	%

(1)	Amounts represent a non-cash expense recorded to adjust the reserve for missing medical equipment and is being added back due to its similarity to depreciation.
(2)	Net Income Margin is defined as GAAP Net Income as a percentage of GAAP Net Revenues.
(3)	Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted EBITDA as a percentage of GAAP Net Revenues.

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (UNAUDITED)
		As of
(in thousands, except par value and share data)		September 30, 2024				December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents		$	380			$	231
Accounts receivable, net			22,761				19,830
Inventories, net			6,700				6,402
Other current assets			3,772				4,157
Total current assets			33,613				30,620
Medical equipment for sale or rental			4,699				3,049
Medical equipment in rental service, net of accumulated depreciation			37,001				34,928
Property & equipment, net of accumulated depreciation			3,910				4,321
Goodwill			3,710				3,710
Intangible assets, net			6,704				7,446
Operating lease right of use assets			5,735				6,703
Deferred income taxes			7,815				9,115
Derivative financial instruments			1,107				1,442
Other assets			1,009				1,581
Total assets		$	105,303			$	102,915
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	8,908			$	8,009
Other current liabilities			8,028				7,704
Total current liabilities			16,936				15,713
Long-term debt, net of current portion			27,975				29,101
Operating lease liabilities, net of current portion			4,879				5,799
Total liabilities			49,790				50,613
Stockholders’ equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued			—				—
Common stock, $0.0001 par value: authorized 200,000,000 shares; 21,234,303 issued and outstanding as of September 30, 2024 and 21,196,851 issued and outstanding as of December 31, 2023			2				2
Additional paid-in capital			112,869				109,837
Accumulated other comprehensive income			836				1,088
Retained deficit			(58,194	)			(58,625	)
Total stockholders’ equity			55,513				52,302
Total liabilities and stockholders’ equity		$	105,303			$	102,915

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
		Nine Months Ended September 30,
(in thousands)			2024				2023
OPERATING ACTIVITIES
Net income		$	1,412			$	800
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts			(141	)			(122	)
Depreciation			8,335				8,621
Loss on disposal of and reserve adjustments for medical equipment			678				1,278
Gain on sale of medical equipment			(1,863	)			(1,990	)
Amortization of intangible assets			743				743
Amortization of deferred debt issuance costs			58				99
Stock-based compensation			3,276				2,799
Deferred income taxes			1,383				325
Changes in assets - (increase)/decrease:
Accounts receivable			(1,348	)			(1,035	)
Inventories			(298	)			(1,270	)
Other current assets			385				(1,090	)
Other assets			1,137				(2,304	)
Changes in liabilities - (decrease)/increase:
Accounts payable and other liabilities			(1,229	)			(289	)
NET CASH PROVIDED BY OPERATING ACTIVITIES			12,528				6,565
INVESTING ACTIVITIES
Purchase of medical equipment			(12,162	)			(8,503	)
Purchase of property and equipment			(562	)			(616	)
Proceeds from sale of medical equipment, property and equipment			2,754				3,429
NET CASH USED IN INVESTING ACTIVITIES			(9,970	)			(5,690	)
FINANCING ACTIVITIES
Principal payments on long-term debt			(40,415	)			(43,160	)
Cash proceeds from long-term debt			39,231				42,788
Debt issuance costs			—				(229	)
Common stock repurchased as part of share repurchase program			(981	)			(153	)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans			(625	)			(1,157	)
Cash proceeds from exercise of options and ESPP			381				1,032
NET CASH USED IN FINANCING ACTIVITIES			(2,409	)			(879	)
Net change in cash and cash equivalents			149				(4	)
Cash and cash equivalents, beginning of period			231				165
Cash and cash equivalents, end of period		$	380			$	161

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107962236/en/

Joe Dorame, Joe Diaz & Robert Blum

Lytham Partners, LLC

602-889-9700

Source: InfuSystem Holdings, Inc.

FAQ

What was InfuSystem's (INFU) revenue growth in Q3 2024?

InfuSystem reported record net revenues of $35.3 million in Q3 2024, representing an 11% increase compared to the same period last year.

How much did InfuSystem's (INFU) net income increase in Q3 2024?

InfuSystem's net income increased 162.3% to $1.8 million ($0.08 per diluted share) in Q3 2024, compared to $0.7 million ($0.03 per diluted share) in Q3 2023.

What was InfuSystem's (INFU) Adjusted EBITDA margin in Q3 2024?

InfuSystem's Adjusted EBITDA margin increased to 22.3% in Q3 2024, up 2.8% from 19.5% in the prior year quarter.